Published in Hepatology on October 01, 2011
Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma. Liver Transpl (2012) 2.32
Superior survival using living donors and donor-recipient matching using a novel living donor risk index. Hepatology (2014) 1.12
Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant (2012) 1.10
Risk factors for frequent readmissions and barriers to transplantation in patients with cirrhosis. PLoS One (2013) 0.98
Quality of life, risk assessment, and safety research in liver transplantation: new frontiers in health services and outcomes research. Curr Opin Organ Transplant (2012) 0.87
Complications and Their Resolution in Recipients of Deceased and Living Donor Liver Transplants: Findings From the A2ALL Cohort Study. Am J Transplant (2015) 0.86
Defining long-term outcomes with living donor liver transplantation in North America. Ann Surg (2015) 0.82
Living Donor Liver Transplant is a Transparent Activity in India. J Clin Exp Hepatol (2012) 0.79
Living donor liver transplantation in the USA. Hepatobiliary Surg Nutr (2016) 0.79
Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study. Hepatology (2014) 0.78
HLA-G polymorphism (rs16375) and acute rejection in liver transplant recipients. Dis Markers (2014) 0.77
Changes in liver and spleen volumes after living liver donation: a report from the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL). Liver Transpl (2015) 0.77
Living donor liver transplantation in Europe. Hepatobiliary Surg Nutr (2016) 0.75
Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients. Liver Transpl (2016) 0.75
Benefit of living donor liver transplantation: who and when? Hepatology (2011) 0.75
Patterns of Early Allograft Dysfunction in Adult Live Donor Liver Transplantation: The A2ALL Experience. Transplantation (2016) 0.75
Living donor liver transplantation: eliminating the wait for death in end-stage liver disease? Nat Rev Gastroenterol Hepatol (2017) 0.75
Impact of Graft Selection on Donor and Recipient Outcomes After Living Donor Liver Transplantation. Transplantation (2016) 0.75
Clinical Impacts of Donor Types of Living vs. Deceased Donors: Predictors of One-Year Mortality in Patients with Liver Transplantation. J Korean Med Sci (2017) 0.75
Hepatic hemodynamics and portal flow modulation: The A2ALL experience. Transplantation (2017) 0.75
A model to predict survival in patients with end-stage liver disease. Hepatology (2001) 18.06
Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology (2003) 10.11
Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant (2006) 8.03
The survival benefit of liver transplantation. Am J Transplant (2005) 5.08
Survival benefit-based deceased-donor liver allocation. Am J Transplant (2009) 2.89
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
Improving liver allocation: MELD and PELD. Am J Transplant (2004) 2.14
Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology (2006) 1.93
Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant (2007) 1.70
Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology (2001) 1.53
Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis. Transplantation (2001) 1.16
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology (2003) 10.11
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med (2003) 8.47
The burden of selected digestive diseases in the United States. Gastroenterology (2002) 6.79
Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med (2002) 6.64
Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology (2004) 5.83
Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. Am J Clin Nutr (2008) 5.01
Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology (2003) 4.95
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
The prevalence of celiac disease in the United States. Am J Gastroenterol (2012) 4.77
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl (2012) 4.65
A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. Transplantation (2009) 4.45
Daily activity energy expenditure and mortality among older adults. JAMA (2006) 4.36
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology (2008) 4.26
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Burden of liver disease in the United States: summary of a workshop. Hepatology (2002) 4.00
Renal transplantation in elderly patients older than 70 years of age: results from the Scientific Registry of Transplant Recipients. Transplantation (2007) 3.69
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology (2007) 3.57
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology (2004) 3.45
Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors. Transplantation (2002) 3.42
Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology (2007) 3.40
Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology (2014) 3.29
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology (2005) 3.12
Relationship of hepatitis C virus infection with diabetes in the U.S. population. Hepatology (2014) 3.04
The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol (2003) 3.04
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Clinical practice. Microscopic hematuria. N Engl J Med (2003) 2.96
Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg (2009) 2.95
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79
A population-based cohort study comparing laparoscopic cholecystectomy and open cholecystectomy. Am J Gastroenterol (2002) 2.75
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch Neurol (2004) 2.71
Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. Liver Transpl (2014) 2.71
Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol (2007) 2.69
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology (2002) 2.64
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg (2005) 2.64
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology (2008) 2.63
Clinical risk factors for portopulmonary hypertension. Hepatology (2008) 2.62
Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol (2002) 2.55
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J Infect Dis (2009) 2.53
Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol (2005) 2.51
Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl (2013) 2.48
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc (2006) 2.43
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology (2003) 2.38
A survey of liver transplantation from living adult donors in the United States. N Engl J Med (2003) 2.37
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2008) 2.30
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26
Expanded criteria donors for kidney transplantation. Am J Transplant (2003) 2.25
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Rates of solid-organ wait-listing, transplantation, and survival among residents of rural and urban areas. JAMA (2008) 2.24
Steroid use in acute liver failure. Hepatology (2013) 2.23
Vascular complications of orthotopic liver transplantation: experience in more than 4,200 patients. J Am Coll Surg (2009) 2.16
Liver transplantation for hepatocellular carcinoma. Gastroenterology (2005) 2.15
Improving liver allocation: MELD and PELD. Am J Transplant (2004) 2.14
Liver transplantation in highest acuity recipients: identifying factors to avoid futility. Ann Surg (2014) 2.13
Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol (2004) 2.12
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death. Liver Transpl (2013) 2.07
Activity energy expenditure and incident cognitive impairment in older adults. Arch Intern Med (2011) 2.07
Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med (2007) 2.07
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology (2006) 1.98
Survival following liver transplantation from non-heart-beating donors. Ann Surg (2004) 1.96
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95
Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population. Am J Gastroenterol (2013) 1.95
Racial and ethnic disparities in access to liver transplantation. Liver Transpl (2010) 1.94
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation (2006) 1.94
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93